Why Compounded Semaglutide Is Mixed With B12

Cyanocobalamin is vitamin B12, and it is in the vial because a compounder put it there — the approved semaglutide injection lists no vitamin among its ingredients at all.^[7] Three different reasons for the pairing get offered to buyers, and only one of them has a federal document standing behind it.

Read the label as two separate facts

A vial reading semaglutide/cyanocobalamin is telling you two things at once. The first is the second ingredient. The second, and the more consequential one, is that nobody manufactures that pairing under an approved application — a two-ingredient injection of this kind exists only because someone mixed it.

The comparison is easy to check. Section 11 of the Ozempic label lists semaglutide alongside disodium phosphate dihydrate, propylene glycol, phenol and water for injections. That is the whole list, and no form of vitamin B12 appears anywhere on it.^[7]

FDA has written about this exact pairing by name

This is the part most coverage of the question misses. FDA did not leave compounded GLP-1 combinations to be argued about in the abstract — it used semaglutide plus B12 as its own illustration when it set out how the “essentially a copy” restriction applies.^[1]

FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy…

— FDA, compounder policy update, April 1, 2026

The sentence ends “…of a commercially available drug product,” and the agency then gave the two conditions that make that judgment bite: the compounded product is given by the same route as the products already on the market — both injectable — and the amounts of semaglutide and of B12 sit within 10 percent of the strengths of those respective products.^[1] Adding a second ingredient, in other words, is not on its own a way out of the restriction.

There is a way out, and it is narrow. Federal law bars a compounder from preparing, regularly or in inordinate amounts, drug products that are essentially copies of a commercially available one, and it defines the phrase so as to exclude a product carrying a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner.^[2] FDA restates the same requirement as a prescriber determination that is documented.^[1] Every load-bearing word there is singular: one patient, one prescriber, one written finding. A formulation offered to everyone who fills out the same intake form is not what that sentence describes.

One threshold is worth knowing because it explains why the restriction rarely bites on a small pharmacy and always bites on a subscription program: FDA has said it does not intend to act on the copy restriction against a compounder filling four or fewer prescriptions of that product in a calendar month.^[1]

The three explanations, side by side

What the published record contains, and what it does not

Two papers touch the combination directly, and neither is a trial of it. The first, in Annals of Pharmacotherapy in 2026, is an editorial-classified survey by pharmacy researchers who searched compounder websites and catalogued what was actually for sale. Their assessment of the nutrient additives was blunt, and it is their assessment rather than a measured result: little justification for putting them there.^[5]

The second is a retrospective look at 94 people at a commercial wellness studio who received weekly semaglutide/cyanocobalamin, titrated so that both components rose together — 0.25 mg with 0.125 mg at the start, up to 2.4 mg with 0.24 mg. Average weight loss at three months was about 4 kg.^[6] The number is real. What it is not is evidence about the B12, because there was no arm without it. A single-arm study of a two-ingredient product can never tell you which ingredient did the work.

The trade you are actually making

This is not an argument that a compounded vial is dangerous, and pharmacy compounding is an ordinary part of American medicine. The point is narrower. FDA does not review a compounded drug for safety, effectiveness or quality before it reaches a patient,^[3] and that gap covers the entire preparation — the vitamin, the concentration and the semaglutide as one object, not just the active ingredient you recognize.

Concentration is where that becomes practical rather than theoretical. FDA has received multiple adverse event reports, some involving hospitalization, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect doses and in some cases from clinicians miscalculating them.^[4] A vial that is not the approved product is a vial whose markings, strength and units you cannot check against an approved label.

Four questions worth putting to the pharmacy

1. What is the B12 strength in my vial, and does it scale when my semaglutide dose goes up? In the one published dataset the two rose together at a fixed ratio.^[6] Whether yours does is a question your pharmacy can answer in one line.
2. Who determined that this formulation is a significant difference for me, and where is that documented? This is the precise wording the exception rests on.^[2] A program that treats it as a house recipe has not met it.
3. Which pharmacy compounded it, and is it state-licensed? FDA's instruction to anyone buying prescription medicine is to fill it at a state-licensed pharmacy, and a name you can look up is the whole point.^[4] Where a seller will not name one, we say so in the provider register.
4. What is the concentration, and how many units is one dose? Ask for it in the units printed on your syringe, not in milligrams alone. The reported dosing errors came from exactly this arithmetic.^[4]

If the answer to any of these is a brand promise rather than a number or a name, that is the answer. Our breakdown of which GLP-1s can still be lawfully compounded covers the rest of the rule this sits inside, and the price tracker shows what the market is doing.